Skip to main content

Table 2 Effect of hypertonic saline and furosemide on plasma concentrations of electrolytes in a randomized, cross-over study of 24 healthy subjects

From: Effect of 3% saline and furosemide on biomarkers of kidney injury and renal tubular function and GFR in healthy subjects – a randomized controlled trial

Period

Baseline (90 min)

After 60 min hypertonic saline infusion (150 min)

90 min post hypertonic saline infusion (240 min)

P-value (difference in response)

p-Na (mmol/L)

 Placebo

140 ± 2

144 ± 2*

141 ± 2*

0.073

 Furosemide

139 ± 2

144 ± 2*

141 ± 2*

p-K (mmol/L)

 Placebo

3.8 ± 0.2

3.7 ± 0.2*

4.0 ± 0.2*

0.001

 Furosemide

3.7 ± 0.2

3.5 ± 0.2*, †

3.8 ± 0.2

p-Cl(mmol/L)

 Placebo

105 ± 2

111 ± 2*

107 ± 2*

< 0.001

 Furosemide

104 ± 2

108 ± 2*, †

104 ± 2*, †

p-Osmolality (mmol/L)

 Placebo

282 ± 4

289 ± 3*

286 ± 4*

0.034

 Furosemide

282 ± 3

291 ± 3*, †

286 ± 3*

p-total carbondioxide (mmol/L)

 Placebo

27 ± 2

25 ± 2*

25 ± 2*

< 0.001

 Furosemide

26 ± 2

26 ± 2

27 ± 2

  1. p-Na Plasma concentrations of sodium, p-K potassium, p-Cl chloride and total carbondioxide and plasma osmolality were measured every 30 min during examination. Data show are values before hypertonic saline infusion, after 60 min of saline infusion, and 90 min after cessation of saline infusion on the examination day. Data are shown as medians with 25 and 75 percentiles in brackets. P-value represents probability of difference in response to saline (response from baseline to saline infusion) between treatments. To test difference in response to saline between treatments a students t-test was used. Wilcoxon signed rank test was performed to test differences from baseline, * = p < 0.05, and from Placebo,  = p < 0.05